|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: MEAF6 |
Gene summary for MEAF6 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | MEAF6 | Gene ID | 64769 |
| Gene name | MYST/Esa1 associated factor 6 | |
| Gene Alias | C1orf149 | |
| Cytomap | 1p34.3 | |
| Gene Type | protein-coding | GO ID | GO:0006464 | UniProtAcc | Q9HAF1 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 64769 | MEAF6 | LZE2D | Human | Esophagus | HGIN | 3.25e-02 | 2.41e-02 | 0.0642 |
| 64769 | MEAF6 | LZE2T | Human | Esophagus | ESCC | 3.82e-05 | 8.64e-01 | 0.082 |
| 64769 | MEAF6 | LZE4T | Human | Esophagus | ESCC | 2.95e-19 | 3.90e-01 | 0.0811 |
| 64769 | MEAF6 | LZE7T | Human | Esophagus | ESCC | 4.33e-13 | 8.13e-01 | 0.0667 |
| 64769 | MEAF6 | LZE8T | Human | Esophagus | ESCC | 1.20e-11 | 3.93e-01 | 0.067 |
| 64769 | MEAF6 | LZE20T | Human | Esophagus | ESCC | 7.85e-11 | 6.12e-01 | 0.0662 |
| 64769 | MEAF6 | LZE22D1 | Human | Esophagus | HGIN | 4.30e-03 | 2.51e-01 | 0.0595 |
| 64769 | MEAF6 | LZE22T | Human | Esophagus | ESCC | 1.87e-05 | 8.18e-01 | 0.068 |
| 64769 | MEAF6 | LZE24T | Human | Esophagus | ESCC | 7.20e-35 | 1.17e+00 | 0.0596 |
| 64769 | MEAF6 | LZE6T | Human | Esophagus | ESCC | 6.43e-12 | 7.29e-01 | 0.0845 |
| 64769 | MEAF6 | P1T-E | Human | Esophagus | ESCC | 1.02e-12 | 8.96e-01 | 0.0875 |
| 64769 | MEAF6 | P2T-E | Human | Esophagus | ESCC | 8.42e-54 | 9.86e-01 | 0.1177 |
| 64769 | MEAF6 | P4T-E | Human | Esophagus | ESCC | 1.80e-41 | 7.93e-01 | 0.1323 |
| 64769 | MEAF6 | P5T-E | Human | Esophagus | ESCC | 4.36e-39 | 8.24e-01 | 0.1327 |
| 64769 | MEAF6 | P8T-E | Human | Esophagus | ESCC | 6.12e-43 | 9.83e-01 | 0.0889 |
| 64769 | MEAF6 | P9T-E | Human | Esophagus | ESCC | 5.13e-21 | 4.58e-01 | 0.1131 |
| 64769 | MEAF6 | P10T-E | Human | Esophagus | ESCC | 3.31e-43 | 8.94e-01 | 0.116 |
| 64769 | MEAF6 | P11T-E | Human | Esophagus | ESCC | 9.99e-13 | 7.77e-01 | 0.1426 |
| 64769 | MEAF6 | P12T-E | Human | Esophagus | ESCC | 2.27e-37 | 6.06e-01 | 0.1122 |
| 64769 | MEAF6 | P15T-E | Human | Esophagus | ESCC | 2.35e-38 | 8.01e-01 | 0.1149 |
| Page: 1 2 3 4 5 6 7 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00182059 | Thyroid | PTC | peptidyl-lysine modification | 188/5968 | 376/18723 | 1.34e-13 | 7.09e-12 | 188 |
| GO:00183947 | Thyroid | PTC | peptidyl-lysine acetylation | 99/5968 | 169/18723 | 6.54e-13 | 3.08e-11 | 99 |
| GO:00064757 | Thyroid | PTC | internal protein amino acid acetylation | 92/5968 | 160/18723 | 1.80e-11 | 7.06e-10 | 92 |
| GO:00183937 | Thyroid | PTC | internal peptidyl-lysine acetylation | 91/5968 | 158/18723 | 2.04e-11 | 7.91e-10 | 91 |
| GO:00165737 | Thyroid | PTC | histone acetylation | 88/5968 | 152/18723 | 2.97e-11 | 1.10e-09 | 88 |
| GO:00439677 | Thyroid | PTC | histone H4 acetylation | 45/5968 | 67/18723 | 3.16e-09 | 8.63e-08 | 45 |
| GO:00439684 | Thyroid | PTC | histone H2A acetylation | 14/5968 | 17/18723 | 2.62e-05 | 2.56e-04 | 14 |
| GO:00439663 | Thyroid | PTC | histone H3 acetylation | 34/5968 | 61/18723 | 9.78e-05 | 8.05e-04 | 34 |
| GO:00439812 | Thyroid | PTC | histone H4-K5 acetylation | 10/5968 | 15/18723 | 5.94e-03 | 2.64e-02 | 10 |
| GO:00439822 | Thyroid | PTC | histone H4-K8 acetylation | 10/5968 | 15/18723 | 5.94e-03 | 2.64e-02 | 10 |
| GO:001657017 | Thyroid | ATC | histone modification | 243/6293 | 463/18723 | 2.23e-17 | 2.27e-15 | 243 |
| GO:001820516 | Thyroid | ATC | peptidyl-lysine modification | 193/6293 | 376/18723 | 6.92e-13 | 3.06e-11 | 193 |
| GO:000647315 | Thyroid | ATC | protein acetylation | 116/6293 | 201/18723 | 1.75e-12 | 7.33e-11 | 116 |
| GO:004354315 | Thyroid | ATC | protein acylation | 134/6293 | 243/18723 | 3.46e-12 | 1.40e-10 | 134 |
| GO:001839415 | Thyroid | ATC | peptidyl-lysine acetylation | 100/6293 | 169/18723 | 7.65e-12 | 2.91e-10 | 100 |
| GO:000647515 | Thyroid | ATC | internal protein amino acid acetylation | 93/6293 | 160/18723 | 1.59e-10 | 4.82e-09 | 93 |
| GO:001839315 | Thyroid | ATC | internal peptidyl-lysine acetylation | 92/6293 | 158/18723 | 1.75e-10 | 5.24e-09 | 92 |
| GO:001657314 | Thyroid | ATC | histone acetylation | 89/6293 | 152/18723 | 2.31e-10 | 6.72e-09 | 89 |
| GO:004396713 | Thyroid | ATC | histone H4 acetylation | 45/6293 | 67/18723 | 2.01e-08 | 3.93e-07 | 45 |
| GO:004396811 | Thyroid | ATC | histone H2A acetylation | 14/6293 | 17/18723 | 5.14e-05 | 3.99e-04 | 14 |
| Page: 1 2 3 4 5 6 7 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| MEAF6 | SNV | Missense_Mutation | c.120C>G | p.Ile40Met | p.I40M | Q9HAF1 | protein_coding | deleterious(0.03) | probably_damaging(0.999) | TCGA-C8-A12K-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| MEAF6 | SNV | Missense_Mutation | c.275C>T | p.Ser92Phe | p.S92F | Q9HAF1 | protein_coding | deleterious(0) | possibly_damaging(0.804) | TCGA-D8-A27V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | |
| MEAF6 | SNV | Missense_Mutation | novel | c.130N>C | p.Glu44Gln | p.E44Q | Q9HAF1 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-HM-A4S6-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Chemotherapy | cisplatin | CR |
| MEAF6 | SNV | Missense_Mutation | c.289G>A | p.Ala97Thr | p.A97T | Q9HAF1 | protein_coding | tolerated(0.36) | benign(0.036) | TCGA-AA-3710-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| MEAF6 | SNV | Missense_Mutation | c.516N>T | p.Lys172Asn | p.K172N | Q9HAF1 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.985) | TCGA-AA-A010-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Chemotherapy | folinic | CR | |
| MEAF6 | SNV | Missense_Mutation | c.332N>C | p.Ile111Thr | p.I111T | Q9HAF1 | protein_coding | tolerated(0.59) | benign(0.014) | TCGA-G4-6588-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| MEAF6 | SNV | Missense_Mutation | novel | c.415N>A | p.Asp139Asn | p.D139N | Q9HAF1 | protein_coding | deleterious(0.03) | benign(0.443) | TCGA-A5-A0G1-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| MEAF6 | SNV | Missense_Mutation | rs868263057 | c.230N>A | p.Arg77Gln | p.R77Q | Q9HAF1 | protein_coding | tolerated(0.05) | benign(0.024) | TCGA-A5-A0G1-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| MEAF6 | SNV | Missense_Mutation | rs868263057 | c.230N>A | p.Arg77Gln | p.R77Q | Q9HAF1 | protein_coding | tolerated(0.05) | benign(0.024) | TCGA-A5-A0GG-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| MEAF6 | SNV | Missense_Mutation | c.239G>A | p.Arg80Gln | p.R80Q | Q9HAF1 | protein_coding | deleterious(0.01) | possibly_damaging(0.732) | TCGA-AJ-A3EK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | carboplatin | CR |
| Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |